Literature DB >> 19181508

High resolution computed tomography and pulmonary function in common variable immunodeficiency.

Stina Gregersen1, Trond Mogens Aaløkken, Georg Mynarek, Johny Kongerud, Pål Aukrust, Stig S Frøland, Bjørn Johansen.   

Abstract

Patients with common variable immunodeficiency (CVID) have impaired production of immunoglobulins and hence recurrent airway infections, which in turn may lead to radiological changes and impaired lung function. Uncertainty exists about the nature and frequency of the radiological and the physiological abnormalities, and how they relate to each other. We reassessed high resolution computed tomography (HRCT) images in 65 patients, reported results from previously measured lung function tests, and studied relations between radiology, function and clinical variables. Airway obstruction, ventilatory restriction and impaired gas diffusion was found in 40, 34 and 21% of the patients, respectively. HRCT abnormalities were present in 94% of the subjects, mild changes being the most common. Bronchial wall thickening, found in two thirds of the patients, was related to airway obstruction and impaired gas diffusion. Linear and/or irregular opacities, the most frequent interstitial abnormality, was related to impaired gas diffusion. Bronchiectasis was found in more than half, but only severe bronchiectasis was related to airway obstruction. Since bronchial wall thickening and linear and/or irregular opacities are both frequent and important determinants of impaired pulmonary function, more attention should be given to these features in the follow up of CVID patients.

Entities:  

Mesh:

Year:  2009        PMID: 19181508     DOI: 10.1016/j.rmed.2008.12.015

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  12 in total

1.  CT screening for pulmonary pathology in common variable immunodeficiency disorders and the correlation with clinical and immunological parameters.

Authors:  L J Maarschalk-Ellerbroek; P A de Jong; J M van Montfrans; J W J Lammers; A C Bloem; A I M Hoepelman; P M Ellerbroek
Journal:  J Clin Immunol       Date:  2014-06-21       Impact factor: 8.317

Review 2.  Immunodeficiencies.

Authors:  M Ballow; L Notarangelo; B Grimbacher; C Cunningham-Rundles; M Stein; M Helbert; B Gathmann; G Kindle; A K Knight; H D Ochs; K Sullivan; J L Franco
Journal:  Clin Exp Immunol       Date:  2009-12       Impact factor: 4.330

3.  Use of combination chemotherapy for treatment of granulomatous and lymphocytic interstitial lung disease (GLILD) in patients with common variable immunodeficiency (CVID).

Authors:  Nicole M Chase; James W Verbsky; Mary K Hintermeyer; Jill K Waukau; Aoy Tomita-Mitchell; James T Casper; Sumit Singh; Kaushik S Shahir; William B Tisol; Melodee L Nugent; R Nagarjun Rao; A Craig Mackinnon; Lawrence R Goodman; Pippa M Simpson; John M Routes
Journal:  J Clin Immunol       Date:  2012-08-29       Impact factor: 8.317

4.  Imaging of Bronchial Pathology in Antibody Deficiency: Data from the European Chest CT Group.

Authors:  Katharina Schütz; Diana Alecsandru; Bodo Grimbacher; Jamanda Haddock; Annemarie Bruining; Gertjan Driessen; Esther de Vries; Peter M van Hagen; Ieneke Hartmann; Francesco Fraioli; Cinzia Milito; Milica Mitrevski; Isabella Quinti; Goffredo Serra; Peter Kelleher; Michael Loebinger; Jiri Litzman; Vera Postranecka; Vojtech Thon; Judith Babar; Alison M Condliffe; Andrew Exley; Dinakantha Kumararatne; Nick Screaton; Alison Jones; Maria P Bondioni; Vassilios Lougaris; Alessandro Plebani; Annarosa Soresina; Cesare Sirignano; Giuseppe Spadaro; Nermeen Galal; Luis I Gonzalez-Granado; Sabine Dettmer; Robert Stirling; Helen Chapel; Mary Lucas; Smita Patel; Claire-Michele Farber; Isabelle Meyts; Arpan K Banerjee; Scott Hackett; John R Hurst; Klaus Warnatz; Benjamin Gathmann; Ulrich Baumann
Journal:  J Clin Immunol       Date:  2018-12-13       Impact factor: 8.317

5.  Human plasma-derived polymeric IgA and IgM antibodies associate with secretory component to yield biologically active secretory-like antibodies.

Authors:  Stéphanie Longet; Sarah Miled; Marius Lötscher; Sylvia M Miescher; Adrian W Zuercher; Blaise Corthésy
Journal:  J Biol Chem       Date:  2012-12-18       Impact factor: 5.157

6.  Activity, severity and impact of respiratory disease in primary antibody deficiency syndromes.

Authors:  John R Hurst; Sarita Workman; Davinder S Garcha; Suranjith L Seneviratne; Jamanda A Haddock; Bodo Grimbacher
Journal:  J Clin Immunol       Date:  2013-10-18       Impact factor: 8.317

7.  Use of FEF25-75% to Guide IgG Dosing to Protect Pulmonary Function in CVID.

Authors:  Tracy Hwangpo; Zhixin Wang; Jack Ghably; Surya P Bhatt; Xiangqin Cui; Harry W Schroeder
Journal:  J Clin Immunol       Date:  2020-01-03       Impact factor: 8.317

8.  Antibody deficiency in patients with frequent exacerbations of Chronic Obstructive Pulmonary Disease (COPD).

Authors:  Brian N McCullagh; Alejandro P Comellas; Zuhair K Ballas; John D Newell; M Bridget Zimmerman; Antoine E Azar
Journal:  PLoS One       Date:  2017-02-17       Impact factor: 3.240

Review 9.  Immune mechanisms and the impact of the disrupted lung microbiome in chronic bacterial lung infection and bronchiectasis.

Authors:  R J Boyton; C J Reynolds; K J Quigley; D M Altmann
Journal:  Clin Exp Immunol       Date:  2013-02       Impact factor: 4.330

10.  Chest CT Manifestations in Children with CVID: A 10-Year Report.

Authors:  Mohammad Reza Boloursaz; Soheila Khalilzadeh; Pegah Rahmati Nezhad; Mehrdad Bakhshayesh Karam; Alireza Mahdaviani; Leila Mosadegh; Maryam Hassanzad; Seyed Mohsen Mir Hosseini
Journal:  Tanaffos       Date:  2012
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.